糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

新型抗VEGF抗体聚合物KSI-301治疗湿性AMD、DME、RVO取得阶段成果

2019-07-29 Allan MedSci原创

湿性AMD抗VEGFKSI-301
关注

Kodiak是一家专注于治疗慢性流行性视网膜疾病的临床阶段生物制药公司，近日公布了正在进行的I期试验的中期结果，该试验研究了玻璃体内注射新型抗VEGF抗体聚合物KSI-301治疗初始新生血管（湿）老年黄斑变性（AMD）、糖尿病性黄斑水肿（DME）和视网膜静脉阻塞（RVO）引起的黄斑水肿患者。

Kodiak是一家专注于治疗慢性流行性视网膜疾病的临床阶段生物制药公司，近日公布了正在进行的I期试验的中期结果，该试验研究了玻璃体内注射新型抗VEGF抗体聚合物KSI-301治疗初始新生血管（湿）老年黄斑变性（AMD）、糖尿病性黄斑水肿（DME）和视网膜静脉阻塞（RVO）引起的黄斑水肿患者。研究结果由Pravin U.Dugel博士在2019年美国视网膜专家协会（ASRS）上公布。

在所研究的三种疾病中，观察到在12周内视力和视网膜解剖学的显著改善，包括最佳校正视力（BCVA）的改善和视网膜中央子场厚度（CST）的改善。


原始出处：

http://www.firstwordpharma.com/node/1655362#axzz5v3ifAwvT

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1197849, encodeId=7ef2119e849fb, content=2022年结果， IIb / III 期试验失败了，表明1期结果并不能说明问题<a href='/topic/show?id=c329103136f1' target=_blank style='color:#2F92EE;'>#黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103136, encryptionId=c329103136f1, topicName=黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Feb 27 22:29:38 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316006, encodeId=a1b413160067d, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368529, encodeId=8e9213685291a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10580, encryptionId=5c811058084, topicName=KSI-301)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a910754704, createdName=12498aa2m65(暂无昵称), createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521291, encodeId=fce1152129190, content=<a href='/topic/show?id=98bc80e9418' target=_blank style='color:#2F92EE;'>#聚合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80794, encryptionId=98bc80e9418, topicName=聚合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf611326764, createdName=yese, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621239, encodeId=aca51621239b7, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629124, encodeId=03de1629124d2, content=<a href='/topic/show?id=7a1a604538' target=_blank style='color:#2F92EE;'>#DME#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6045, encryptionId=7a1a604538, topicName=DME)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713521313796, createdName=徐岩, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2022-02-27 医者仁者

    2022年结果， IIb / III 期试验失败了，表明1期结果并不能说明问题#黄斑变性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1197849, encodeId=7ef2119e849fb, content=2022年结果， IIb / III 期试验失败了，表明1期结果并不能说明问题<a href='/topic/show?id=c329103136f1' target=_blank style='color:#2F92EE;'>#黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103136, encryptionId=c329103136f1, topicName=黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Feb 27 22:29:38 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316006, encodeId=a1b413160067d, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368529, encodeId=8e9213685291a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10580, encryptionId=5c811058084, topicName=KSI-301)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a910754704, createdName=12498aa2m65(暂无昵称), createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521291, encodeId=fce1152129190, content=<a href='/topic/show?id=98bc80e9418' target=_blank style='color:#2F92EE;'>#聚合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80794, encryptionId=98bc80e9418, topicName=聚合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf611326764, createdName=yese, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621239, encodeId=aca51621239b7, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629124, encodeId=03de1629124d2, content=<a href='/topic/show?id=7a1a604538' target=_blank style='color:#2F92EE;'>#DME#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6045, encryptionId=7a1a604538, topicName=DME)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713521313796, createdName=徐岩, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2019-07-31 zhty5337

    #AMD#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1197849, encodeId=7ef2119e849fb, content=2022年结果， IIb / III 期试验失败了，表明1期结果并不能说明问题<a href='/topic/show?id=c329103136f1' target=_blank style='color:#2F92EE;'>#黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103136, encryptionId=c329103136f1, topicName=黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Feb 27 22:29:38 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316006, encodeId=a1b413160067d, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368529, encodeId=8e9213685291a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10580, encryptionId=5c811058084, topicName=KSI-301)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a910754704, createdName=12498aa2m65(暂无昵称), createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521291, encodeId=fce1152129190, content=<a href='/topic/show?id=98bc80e9418' target=_blank style='color:#2F92EE;'>#聚合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80794, encryptionId=98bc80e9418, topicName=聚合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf611326764, createdName=yese, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621239, encodeId=aca51621239b7, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629124, encodeId=03de1629124d2, content=<a href='/topic/show?id=7a1a604538' target=_blank style='color:#2F92EE;'>#DME#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6045, encryptionId=7a1a604538, topicName=DME)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713521313796, createdName=徐岩, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2019-07-31 fanweitanzhen

    #VEGF#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1197849, encodeId=7ef2119e849fb, content=2022年结果， IIb / III 期试验失败了，表明1期结果并不能说明问题<a href='/topic/show?id=c329103136f1' target=_blank style='color:#2F92EE;'>#黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103136, encryptionId=c329103136f1, topicName=黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Feb 27 22:29:38 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316006, encodeId=a1b413160067d, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368529, encodeId=8e9213685291a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10580, encryptionId=5c811058084, topicName=KSI-301)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a910754704, createdName=12498aa2m65(暂无昵称), createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521291, encodeId=fce1152129190, content=<a href='/topic/show?id=98bc80e9418' target=_blank style='color:#2F92EE;'>#聚合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80794, encryptionId=98bc80e9418, topicName=聚合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf611326764, createdName=yese, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621239, encodeId=aca51621239b7, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629124, encodeId=03de1629124d2, content=<a href='/topic/show?id=7a1a604538' target=_blank style='color:#2F92EE;'>#DME#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6045, encryptionId=7a1a604538, topicName=DME)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713521313796, createdName=徐岩, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2019-07-31 12498aa2m65(暂无昵称)

    #KSI-301#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1197849, encodeId=7ef2119e849fb, content=2022年结果， IIb / III 期试验失败了，表明1期结果并不能说明问题<a href='/topic/show?id=c329103136f1' target=_blank style='color:#2F92EE;'>#黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103136, encryptionId=c329103136f1, topicName=黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Feb 27 22:29:38 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316006, encodeId=a1b413160067d, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368529, encodeId=8e9213685291a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10580, encryptionId=5c811058084, topicName=KSI-301)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a910754704, createdName=12498aa2m65(暂无昵称), createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521291, encodeId=fce1152129190, content=<a href='/topic/show?id=98bc80e9418' target=_blank style='color:#2F92EE;'>#聚合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80794, encryptionId=98bc80e9418, topicName=聚合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf611326764, createdName=yese, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621239, encodeId=aca51621239b7, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629124, encodeId=03de1629124d2, content=<a href='/topic/show?id=7a1a604538' target=_blank style='color:#2F92EE;'>#DME#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6045, encryptionId=7a1a604538, topicName=DME)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713521313796, createdName=徐岩, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2019-07-31 yese

    #聚合物#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1197849, encodeId=7ef2119e849fb, content=2022年结果， IIb / III 期试验失败了，表明1期结果并不能说明问题<a href='/topic/show?id=c329103136f1' target=_blank style='color:#2F92EE;'>#黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103136, encryptionId=c329103136f1, topicName=黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Feb 27 22:29:38 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316006, encodeId=a1b413160067d, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368529, encodeId=8e9213685291a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10580, encryptionId=5c811058084, topicName=KSI-301)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a910754704, createdName=12498aa2m65(暂无昵称), createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521291, encodeId=fce1152129190, content=<a href='/topic/show?id=98bc80e9418' target=_blank style='color:#2F92EE;'>#聚合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80794, encryptionId=98bc80e9418, topicName=聚合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf611326764, createdName=yese, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621239, encodeId=aca51621239b7, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629124, encodeId=03de1629124d2, content=<a href='/topic/show?id=7a1a604538' target=_blank style='color:#2F92EE;'>#DME#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6045, encryptionId=7a1a604538, topicName=DME)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713521313796, createdName=徐岩, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2019-07-31 d830379

    #抗VEGF#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1197849, encodeId=7ef2119e849fb, content=2022年结果， IIb / III 期试验失败了，表明1期结果并不能说明问题<a href='/topic/show?id=c329103136f1' target=_blank style='color:#2F92EE;'>#黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103136, encryptionId=c329103136f1, topicName=黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Feb 27 22:29:38 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316006, encodeId=a1b413160067d, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368529, encodeId=8e9213685291a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10580, encryptionId=5c811058084, topicName=KSI-301)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a910754704, createdName=12498aa2m65(暂无昵称), createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521291, encodeId=fce1152129190, content=<a href='/topic/show?id=98bc80e9418' target=_blank style='color:#2F92EE;'>#聚合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80794, encryptionId=98bc80e9418, topicName=聚合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf611326764, createdName=yese, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621239, encodeId=aca51621239b7, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629124, encodeId=03de1629124d2, content=<a href='/topic/show?id=7a1a604538' target=_blank style='color:#2F92EE;'>#DME#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6045, encryptionId=7a1a604538, topicName=DME)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713521313796, createdName=徐岩, createdTime=Wed Jul 31 09:10:00 CST 2019, time=2019-07-31, status=1, ipAttribution=)]
    2019-07-31 徐岩

    #DME#

    0